Newspatrolling.com News cum Content Syndication Portal Online
Mumbai, May 02, 2025: SunAct – Advanced Cancer Therapies, the Oncology start-up founded by Dr. Vijay Patil and Dr. Ashay Karpe, aimed at making the world’s most advanced and innovative cancer care accessible and affordable in the country, today launched their third facility in India and the first in Mumbai city, at the Dr. Gupte Surgical Hospital in Khar (West). The new centre will offer India’s first CAR-T for solid-state tumours along with various therapies which will be introduced in India via SunAct.
The centre was inaugurated on the auspicious occasion of Akshay Trithi by Dr. Sudhir Gupte as the Chief Guest for the event. The other dignitaries present along with him were Dr (Prof.) Vijay Patil – Founder & Professor of SunAct – Advanced Cancer Therapies, Dr. Ashay Kharpe – Co-founder, SunAct – Advanced Cancer Therapies, Mr. Kushagra Sharma – Chief Executive Officer, SunAct – Advanced Cancer Therapies and the Guest of Honour for the evening, Dr. Kumar Prabhash – Professor & Head, Department of Medical Oncology (Solid Tumors) at Tata Memorial Hospital, Mumbai.
Dr. Sudhir Gupte, acclaimed Obstetrician & Gynaecologist, addressing the gathering said, “What began as a humble nine-bed nursing home in an undeveloped Khar in 1929 has grown with the blessings of our forefathers and the community. Today, I see the same healing energy continuing with SunAct’s new Centre, and I’m confident this collaboration will bring advanced cancer care to many more lives.”
Dr. (Prof.) Vijay Patil, acclaimed Oncologist and Founder of SunAct – Advanced Cancer Therapies, sharing his thoughts on the occasion said, “This launch reflects not just growth, but a purposeful movement toward accessibility and equity in cancer care. At SunAct, our aim is to ensure that geography never determines the quality of treatment one receives. The Khar centre is a vital step in turning that vision into reality—making cutting-edge therapies available in local neighbourhoods, where healing truly begins.”
Also expressing immense satisfaction was Dr. Ashay Karpe’, Co-founder, SunAct – Advanced Cancer Therapies: “Team SunAct has pledged to provide a state-of-the-art line of treatment for advanced cancers. With this mission, we are inaugurating a new centre in Khar to provide wider coverage to patients. Combining newer therapies with meaningful clinical research and partnering with global cancer care institutions. SunAct aims to make advanced cancer care solutions more accessible to the public.”
Addressing a question on SunAct’s plans for the future, Mr. Kushagra Sharma, CEO, SunAct-Advanced Cancer Therapies said, “We definitely aim to expand all over India including in Maharashtra. The idea is to spread awareness through marketing, through social media and also to spread awareness among more and more doctors that these treatments are now available in India.”
National First: CAR T-Cell Therapy for Solid Tumors—Now in Khar
In a defining moment for Indian oncology, SunAct’s Khar centre will not only offer CAR-T for haematological cancers like Lymphoma, Leukemia and Myeloma, but it is also India’s first CAR T-cell therapy for solid tumours, a revolutionary approach previously unavailable in the country. In addition to this milestone, the centre will provide:
– TCR (T-Cell Receptor) Therapies
– TIL (Tumor-Infiltrating Lymphocyte) Therapies
– Gamma Delta T-Cell Platforms
– Gene Therapies
– Bone Marrow Transplantation & Clinical Trials
Vision and Impact
SunAct – Advanced Cancer Therapies envisions a future where advanced cancer treatment is accessible to all, regardless of location or socioeconomic status. SunAct aims to bridge the gap in cancer care delivery by strategically opening new centres and forging partnerships.
These initiatives are designed to bring innovative therapies and expert oncological services closer to underserved communities, ensuring equitable access to life-saving treatments and fostering a network of care that extends beyond major metropolitan areas.
A Track Record of Firsts in Indian Oncology
- 2023 – Establishment of SunAct – Advanced Cancer Therapies.
- May–July 2024 – First CAR T-Cell Therapy in India for Rhabdomyosarcoma, Ovarian Cancer, Head & Neck Cancer, and Esophageal Cancer
- August 2024 – First TCR targeting TP53 mutation (Cholangiocarcinoma), First CAR T-Cell for Small Cell Lung Cancer
- September 2024 – First KRAS TCR & HER2+ CAR T-Cell Therapy for Gastric Carcinoma, Colorectal, and Salivary Gland Cancers
- October 2024 – First bispecific CS1-BCMA CAR-T (Relapsed/Refractory Multiple Myeloma), First bispecific TCR targeting TP53 & APC (Colorectal Cancer)
- November 2024 – First Claudin 18.2 CAR-T Therapy for Pancreatic Cancer
- January 2025 – First CAR-T Therapy for Glioblastoma Multiforme (GBM)
- February 2025 – First Dual CD19/CD20 CAR-T Therapy for Diffuse Large B-Cell Lymphoma (DLBCL)
